Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Flor De Maria Munoz

Pediatric Infectious Diseases Houston, TX Medical Doctor

NPI 1689754095 CMS profile 894991

6701 Fannin St, Houston, TX 77030

Open in the dashboard

General payments

$268,070

177 records reported · program years 2019–2025

Research payments

$42,510

Paid to them · 23 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$9,227,446 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Flor De Maria Munoz of Houston, TX is reported in the CMS Open Payments database as having received $268,070 across 177 general payments and $42,510 in research payments paid to them. Separately, studies naming them as principal investigator received $9,227,446 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 97th percentile of Pediatric Infectious Diseases profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

11 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $106,654 55
2025 Research $14,200 1
2024 General $6,390 4
2023 General $37,039 45
2023 Research $1,620 1
2022 General $63,261 29
2022 Research $22,615 19
2021 General $22,969 9
2021 Research $4,075 2
2020 General $11,636 8
2019 General $20,121 27

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Flor De Maria Munoz
  • Pediatric Infectious Diseases median
  • Middle half of Pediatric Infectious Diseases
  • National median

In program year 2025, general payments to Flor De Maria Munoz were reported at $106,654. Among 311 Pediatric Infectious Diseases profiles paid that year, the median was $126 and the middle half received between $41 and $2,094.

Show as a table
Year Flor De Maria Munoz Pediatric Infectious Diseases median Middle half National median
2019 $20,121 $175 $34–$2,175 $163
2020 $11,636 $521 $34–$6,009 $114
2021 $22,969 $1,077 $39–$4,557 $132
2022 $63,261 $232 $53–$6,196 $149
2023 $37,039 $140 $52–$4,662 $160
2024 $6,390 $198 $52–$3,860 $164
2025 $106,654 $126 $41–$2,094 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Sanofi Pasteur Inc. $74,416 43 payments
  2. Merck Sharp & Dohme Corporation $60,748 45 payments
  3. Pfizer Inc. $45,392 15 payments
  4. Moderna TX, Inc. $38,571 31 payments
  5. Sanofi US Services Inc. $22,600 2 payments
  6. AstraZeneca UK Limited $5,771 9 payments
  7. GlaxoSmithKline, LLC. $5,621 13 payments
  8. Dynavax Technologies Corporation $5,500 7 payments
  9. AstraZeneca Pharmaceuticals LP $4,342 5 payments
  10. Seqirus USA Inc $4,216 2 payments
  11. Other $893 5 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $175,516 68 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $55,442 15 payments
  3. Travel and Lodging $34,938 56 payments
  4. Food and Beverage $2,175 38 payments
Products named General payments · program years 2019–2025
  1. ENFLONSIA $22,920 29 payments
  2. Moderna Covid-19 Vaccine $20,390 2 payments
  3. NO PRODUCT DISCUSSED $7,619 5 payments
  4. FLUZONE QUADRIVALENT Vaccines $5,690 3 payments
  5. ADACEL $5,237 4 payments
  6. FLUCELVAX QUADRIVALENT $4,216 2 payments
  7. Heplisav-B $3,500 5 payments
  8. FLUZONE QUADRIVALENT NORTHERN HEMISPHERE $3,290 1 payment
  9. FLUMIST QUADRIVALENT $1,600 1 payment
  10. FLUZONE QUADRIVALENT Vaccines $1,189 5 payments
  11. Other $1,641 18 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Moderna TX, Inc. $21,910 20 payments
  2. Sanofi Pasteur Inc. $14,200 1 payment
  3. Pfizer Inc. $6,400 2 payments

Records

200 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatric Infectious Diseases in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record